How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
作者信息
Pinchinat Ashley, Raetz Elizabeth
机构信息
Department of Pediatrics and Perlmutter Cancer Center NYU Langone Health.
出版信息
Haematologica. 2022 Oct 1;107(10):2292-2294. doi: 10.3324/haematol.2021.280395.
Abstract
摘要
相似文献
1
How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?mTOR抑制剂在复发急性淋巴细胞白血病的治疗格局中如何定位？
Haematologica. 2022 Oct 1;107(10):2292-2294. doi: 10.3324/haematol.2021.280395.
2
Targeting mTOR in Acute Lymphoblastic Leukemia.靶向 mTOR 在急性淋巴细胞白血病中的作用。
Cells. 2019 Feb 21;8(2):190. doi: 10.3390/cells8020190.
3
Oncogene-independent resistance in Philadelphia chromosome - positive (Ph) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway.费城染色体阳性（Ph）急性淋巴细胞白血病（ALL）中的癌基因独立性耐药是由 AKT/mTOR 通路的激活介导的。
Neoplasia. 2021 Sep;23(9):1016-1027. doi: 10.1016/j.neo.2021.07.009. Epub 2021 Aug 14.
4
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model.在临床前模型中针对高危急性淋巴细胞白血病中过度激活的mTOR信号传导
Oncotarget. 2015 Jan 30;6(3):1382-95. doi: 10.18632/oncotarget.2842.
5
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.mTOR 在 T 细胞急性淋巴细胞白血病中的治疗靶点：最新进展。
Int J Mol Sci. 2018 Jun 26;19(7):1878. doi: 10.3390/ijms19071878.
6
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.靶向 B 系急性淋巴细胞白血病中的磷脂酰肌醇 3-激酶/蛋白激酶 B/雷帕霉素靶蛋白信号通路：更新。
J Cell Physiol. 2018 Oct;233(10):6440-6454. doi: 10.1002/jcp.26539. Epub 2018 Apr 18.
7
Beating the Clock in T-cell Acute Lymphoblastic Leukemia.在 T 细胞急性淋巴细胞白血病中争分夺秒。
Clin Cancer Res. 2017 Feb 15;23(4):873-875. doi: 10.1158/1078-0432.CCR-16-2825. Epub 2016 Dec 22.
8
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.靶向PI3K/AKT/mTOR通路或NUP214-ABL1融合蛋白的选择性抑制剂在人类急性淋巴细胞白血病中的协同作用
Oncotarget. 2016 Nov 29;7(48):79842-79853. doi: 10.18632/oncotarget.13035.
9
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.冬凌草甲素联合伊马替尼通过抑制 LYN/mTOR 信号通路激活对 Ph+ 急性淋巴细胞白血病细胞发挥协同抗白血病作用。
Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. Epub 2012 Aug 16.
10
Novel targets for treatment of adult acute lymphocytic leukemia.治疗成人急性淋巴细胞白血病的新靶点。
Curr Hematol Malig Rep. 2010 Oct;5(4):207-12. doi: 10.1007/s11899-010-0064-8.
引用本文的文献
1
Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities.儿童急性淋巴细胞白血病中的蛋白质组学：挑战与机遇
Diagnostics (Basel). 2023 Aug 24;13(17):2748. doi: 10.3390/diagnostics13172748.
本文引用的文献
1
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).替西罗莫司联合环磷酰胺和依托泊苷治疗复发/难治性儿童急性淋巴细胞白血病：儿童白血病治疗进展联盟试验（TACL 2014-001）。
Haematologica. 2022 Oct 1;107(10):2295-2303. doi: 10.3324/haematol.2021.279520.
2
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.达沙替尼联合博纳吐单抗治疗成人费城染色体阳性急性淋巴细胞白血病。
N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.
3
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.在口服酪氨酸激酶抑制剂治疗的同时给予blinatumomab是一种耐受良好的巩固策略，可消除费城染色体阳性急性淋巴细胞白血病成人患者的可测量残留疾病。
Leuk Res. 2019 Apr;79:27-33. doi: 10.1016/j.leukres.2019.02.009. Epub 2019 Feb 23.
4
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.多复发 B 细胞急性淋巴细胞白血病患儿的结局：儿童白血病和淋巴瘤研究的治疗进展。
Leukemia. 2018 Nov;32(11):2316-2325. doi: 10.1038/s41375-018-0094-0. Epub 2018 Mar 15.
5
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.在复发的儿童急性淋巴细胞白血病中，mTOR 抑制剂依维莫司联合多药化疗的 I 期临床试验。
Pediatr Blood Cancer. 2018 Jul;65(7):e27062. doi: 10.1002/pbc.27062. Epub 2018 Mar 30.
6
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).替西罗莫司与强化再诱导化疗用于急性淋巴细胞白血病第二次或更多次复发的1期试验：儿童肿瘤学组研究（ADVL1114）
Br J Haematol. 2017 May;177(3):467-474. doi: 10.1111/bjh.14569. Epub 2017 Mar 14.
7
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.PI3K/mTOR与JAK或ABL联合抑制在Ph样急性淋巴细胞白血病小鼠异种移植模型中的强效疗效。
Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24.
8
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.靶向儿童血液系统恶性肿瘤中的PI3K/mTOR信号通路
Front Oncol. 2014 May 16;4:108. doi: 10.3389/fonc.2014.00108. eCollection 2014.
9
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.复发或难治性急性淋巴细胞白血病患者的治疗结果：儿童白血病治疗进展联盟的一项研究。
J Clin Oncol. 2010 Feb 1;28(4):648-54. doi: 10.1200/JCO.2009.22.2950. Epub 2009 Oct 19.
Zotero 插件